AHR and melanoma: This aligns with clinical data: in advanced melanoma patients receiving anti-PD-1/IFNα, serum I3A levels >31.15 pmol/100 μL (70th percentile) correlate with significantly longer PFS (12.6 vs. 5.8 months) and OS (28.3 vs. 14.1 months), whereas non-responders show no differences in levels of the endogenous AhR ligand Kyn—confirming I3A-specific effects (113).